WELWYN GARDEN CITY, England and BOSTON, March 1, 2013 /PRNewswire/ --
Heptares Therapeutics, the leading GPCR drug discovery company, announces that Malcolm Weir (Heptares CEO) will attend the 6th Annual European Life Science CEO Forum taking place on the at the Hilton Zurich Airport Hotel, Zurich, Switzerland (5-6 March), at which he will participate in a panel discussion on Platform Technologies and Novel Therapeutics (2:00pm-3:15pm, 5 March). Dr Weir will also present an overview of the company at the event (5 March, 11:45am in Panorama B).
Dr Weir and Barry Kenny (Chief Business Officer) will also attend BIO-Europe Spring 2013 at the CCIB Convention Centre, Barcelona, Spain (11-13 March).
For a full list of events at which Heptares will be present, please visit http://www.heptares.com
About Heptares Therapeutics
Heptares creates new medicines targeting clinically important, yet historically challenging, GPCRs (G protein-coupled receptors), a superfamily of drug receptors linked to a wide range of human diseases. Leveraging our advanced structure-based drug design technology platform, we have built an exciting discovery and development pipeline of novel drug candidates, which have the potential to transform the treatment of serious diseases, including Alzheimer's disease, Parkinson's disease, schizophrenia, migraine and diabetes. Our pharmaceutical partners include Shire, Cubist, Takeda, MorphoSys, AstraZeneca and MedImmune, and we are backed by MVM Life Science Partners, Clarus Ventures, Novartis Venture Fund and Takeda Ventures. To learn more about Heptares, please visit http://www.heptares.com.
SOURCE Heptares Therapeutics